Role of cardiac steatosis and lipotoxicity in obesity cardiomyopathy

Hypertension

Volumn 57, Issue 2, 2011, Pages 148-150

  Zhang, Yingmei ^a,b   Ren, Jun ^b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF WYOMING COLLEGE OF HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLCARNITINE; CERAMIDE; DIACYLGLYCEROL; DIACYLGLYCEROL ACYLTRANSFERASE 1; GLUCOSE; LIPID; LONG CHAIN FATTY ACID COENZYME A LIGASE; MYOSIN HEAVY CHAIN ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHOSPHATE; TRIACYLGLYCEROL;

ATHEROSCLEROSIS; CARDIAC STEATOSIS; CARDIOMYOPATHY; CHOLESTEROL ESTERIFICATION; FATTY ACID TRANSPORT; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HEART DISEASE; HEART MUSCLE CELL; HEART VENTRICLE FAILURE; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; LIPID METABOLISM; LIPOTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOTE; OBESITY; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PHOSPHATE METABOLISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEATOSIS; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; CARDIOMYOPATHIES; CELLS, CULTURED; DIACYLGLYCEROL O-ACYLTRANSFERASE; FATTY ACIDS; LIPID METABOLISM; MICE; MICE, TRANSGENIC; MODELS, BIOLOGICAL; MYOCARDIUM; MYOCYTES, CARDIAC; OBESITY; TRIGLYCERIDES;

EID: 79551495757     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.110.164178     Document Type: Note

References (14)

1. Lopaschuk GD, Folmes CD, Stanley WC. Cardiac energy metabolism in obesity. Circ Res. 2007;101:335-347.
2. Brindley DN, Kok BP, Kienesberger PC, Lehner R, Dyck JR. Shedding light on the enigma of myocardial lipotoxicity: the involvement of known and putative regulators of fatty acid storage and mobilization. Am J Physiol Endocrinol Metab. 2010;298:E897-E908.
3. Buchanan J, Mazumder PK, Hu P, Chakrabarti G, Roberts MW, Yun UJ, Cooksey RC, Litwin SE, Abel ED. Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology. 2005;146:5341-5349.
4. Christoffersen C, Bollano E, Lindegaard ML, Bartels ED, Goetze JP, Andersen CB, Nielsen LB. Cardiac lipid accumulation associated with diastolic dysfunction in obese mice. Endocrinology. 2003;144: 3483-3490.
5. McGavock JM, Lingvay I, Zib I, Tillery T, Salas N, Unger R, Levine BD, Raskin P, Victor RG, Szczepaniak LS. Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation. 2007;116:1170-1175.
6. Yagyu H, Chen G, Yokoyama M, Hirata K, Augustus A, Kako Y, Seo T, Hu Y, Lutz EP, Merkel M, Bensadoun A, Homma S, Goldberg IJ. Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy. J Clin Invest. 2003;111: 419-426.
7. Chiu HC, Kovacs A, Ford DA, Hsu FF, Garcia R, Herrero P, Saffitz JE, Schaffer JE. A novel mouse model of lipotoxic cardiomyopathy. J Clin Invest. 2001;107:813-822.
8. Chiu HC, Kovacs A, Blanton RM, Han X, Courtois M, Weinheimer CJ, Yamada KA, Brunet S, Xu H, Nerbonne JM, Welch MJ, Fettig NM, Sharp TL, Sambandam N, Olson KM, Ory DS, Schaffer JE. Transgenic expression of fatty acid transport protein 1 in the heart causes lipotoxic cardiomyopathy. Circ Res. 2005;96:225-233.
9. Duncan JG, Bharadwaj KG, Fong JL, Mitra R, Sambandam N, Courtois MR, Lavine KJ, Goldberg IJ, Kelly DP. Rescue of cardiomyopathy in peroxisome proliferator-activated receptor-alpha transgenic mice by deletion of lipoprotein lipase identifies sources of cardiac lipids and peroxisome proliferator- activated receptor-alpha activators. Circulation. 2010;121:426-435.
10. Son NH, Yu S, Tuinei J, Arai K, Hamai H, Homma S, Shulman GI, Abel ED, Goldberg IJ. PPARgamma-induced cardiolipotoxicity in mice is ameliorated by PPARalpha deficiency despite increases in fatty acid oxidation. J Clin Invest. 2010;120:3443-3454.
11. Glenn DJ, Wang F, Nishimoto M, Cruz MC, Uchida Y, Holleran WM, Zhang Y, Yeghiazarians Y, Gardner DG. A murine model of isolated cardiac steatosis leads to cardiomyopathy. Hypertension. 2011;57: 216-222.
12. Liu L, Shi X, Bharadwaj KG, Ikeda S, Yamashita H, Yagyu H, Schaffer JE, Yu YH, Goldberg IJ. Dgat1 expression increases heart triglyceride content but ameliorates lipotoxicity. J Biol Chem. 2009;284:36312-36323.
13. Smith GH, Hall ME, Stec DE, Hall JE. Cardiac-specific Cre-recombinase causes a dose-dependent transient reduction in systolic function. FASEB J. 2010;24:596.3. Abstract.
14. Birch AM, Buckett LK, Turnbull AV. Dgat1 inhibitors as anti-obesity and anti-diabetic agents. Curr Opin Drug Discov Devel. 2010;13:489-496.